{
  "report_rows": [
    {
      "kpi": "Adjusted diluted EPS",
      "prediction": "IN-LINE",
      "answer": "pred ~$3.80 vs. cons $3.77",
      "confidence": "MEDIUM"
    },
    {
      "kpi": "Revenue",
      "prediction": "IN-LINE",
      "answer": "pred ~$2.170B vs. cons $2.164B",
      "confidence": "MEDIUM"
    },
    {
      "kpi": "Equity proxy record growth",
      "prediction": "BEAT",
      "answer": "pred ~12% vs. cons 5%",
      "confidence": "MEDIUM"
    }
  ],
  "guide_rows": [
    {
      "kpi": "FY2027 adjusted EPS growth",
      "prediction": "UNCHANGED",
      "answer": "guide ~8-12% vs. cons ~8.6% growth",
      "confidence": "MEDIUM"
    },
    {
      "kpi": "FY2027 recurring-revenue growth",
      "prediction": "BETTER",
      "answer": "guide ~7-9% vs. cons proxy ~4.6% total-revenue growth, UNVERIFIED",
      "confidence": "LOW"
    },
    {
      "kpi": "FY2027 closed sales",
      "prediction": "BETTER",
      "answer": "guide ~$290-330M vs. cons $290.7M",
      "confidence": "MEDIUM"
    },
    {
      "kpi": "Sales-conversion commentary",
      "prediction": "LOWER",
      "answer": "guide: elongated large-deal cycles, no reliable numeric consensus",
      "confidence": "LOW"
    }
  ],
  "day1_residual_pct": -2.0,
  "day1_confidence": "LOW",
  "day5_residual_pct": -3.5,
  "day5_path": "FOLLOW-THROUGH",
  "day5_rationale": "FOLLOW-THROUGH \u2014 sales-cycle caution keeps pressure on FY2027 estimates",
  "day5_confidence": "LOW"
}